Compare iShares Core MSCI EAFE ETF (IEFA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares Core MSCI EAFE ETF trades at $95.89 (market cap $191.47B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.31B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 82.9× Recursion Pharmaceuticals Inc's market cap, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 41 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| IEFA | RXRX | |
|---|---|---|
Market Cap | $191.47B | $2.31B |
Volume | 11,673,895 | 40,478,768 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $6.79 |
52-Week Low | $85.06 | $2.84 |
Typical Hold Time | 41 Days | 22 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA (iShares Core MSCI EAFE ETF) trades at $96.20, down 1.08% with bearish technical signals from moving averages but neutral oscillators. The ETF provides exposure to developed markets outside North America with $196 billion in assets under management. Recent comparisons highlight its competitive expense ratio of 0.07% and higher dividend yield versus peers like Schwab's SCHF and State Street's SPDW.
The fund faces headwinds from international market volatility and currency risks, though its size and diversification offer stability. Near-term performance may be influenced by global economic conditions and investor rotation away from concentrated U.S. tech exposure. Key support sits at $95 with resistance at $97.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
